Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 2;60(8):3513-3521.
doi: 10.1093/rheumatology/kez052.

Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma

Affiliations

Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma

Gaetane Nocturne et al. Rheumatology (Oxford). .

Abstract

Lymphoma development is the most serious complication of SS and the main factor impacting on mortality rate in patients with this condition. Lymphomas in SS are most commonly extranodal non-Hodgkin B-cell lymphomas of the mucosa-associated lymphoid tissue and frequently arise in salivary glands that are the target of a chronic inflammatory autoimmune process. Extensive work on lymphomagenesis in SS has established that the progression towards B-cell lymphoma is a multistep process related to local chronic antigenic stimulation of B cells. These neoplastic B cells in SS frequently derived from autoreactive clones, most commonly RF-producing B cells, which undergo uncontrolled proliferation and malignant escape. In this review, we highlight the most important recent findings that have enhanced our understanding of lymphoma development in SS, with particular reference to the close link between autoimmunity and lymphomagenesis. We also discuss how the identification of key factors involved in B-cell malignancies may impact on our ability to identify at early stages patients at increased risk of lymphoma with potential significant repercussions for the clinical management of SS patients. Finally, we identified the most promising areas of current and further research with the potential to provide novel basic and translational discoveries in the field. The questions of finding new biomarkers, developing a validated score for predicting lymphoma occurrence and assessing if a better control of disease activity will decrease the risk of lymphoma in primary SS will be the enthralling questions of the next few years.

Keywords: BAFF; MALT; Sjogren’s syndrome; germinal centre; lymphoma.

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Immunohistochemical features of ectopic GCs in the SG of SS Representative microphotographs depicting sequential immunohistochemistry staining for CD3 (T cells), CD20 (B cells), CD21 (follicular dendritic cell networks) and CD138 (plasma cells) identifying ectopic GC in labial salivary gland biopsy of SS patients. GC: germinal centres; SG: salivary glands.
<sc>Fig</sc>. 2
Fig. 2
The 2019 proposed scenario for lymphomagensis in pSS The development of lymphoma in pSS is a multi-step process that is centered on chronic antigenic stimulation. Formation of auto-Ab is favored within GC-like structures leading to the presence of ICs at high concentrations at epithelial sites. These latter stimulate the expansion of RF-reactive B cells. Affinity maturation within GC-like structures gives a selective advantage to auto-immune clones. The activation of these autoreactive B cells is amplified by several factors including BAFF via paracrine and/or autocrine secretion, cytokines such as FLT-3 or IL-14 and the over-activation of the NF-κB pathway. Loss of immune control of genetic origin (TNFAIP3 mutations) and a less effective anti-tumor immunosurveillance at mucosal sites might precipitate the lymphomatous escape. GC: germinal centres; pSS: primary SS.

References

    1. Gottenberg JE, Seror R, Miceli-Richard C. et al.. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8:e59868. - PMC - PubMed
    1. Brito-Zerón P, Ramos-Casals M; EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome. Curr Opin Rheumatol 2014;26:520–7. - PubMed
    1. Weng M-Y, Huang Y-T, Liu M-F, Lu T-H.. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren’s syndrome in Taiwan. Ann Rheum Dis 2012;71:524–7. - PubMed
    1. Theander E, Henriksson G, Ljungberg O. et al.. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796–803. - PMC - PubMed
    1. Johnsen SJ, Brun JG, Gøransson LG. et al.. Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population-based study. Arthritis Care Res 2013;65:816–21. - PubMed